Status:
TERMINATED
Study to Learn About How the Study Medicines Called PF-07976016 and PF-06882961 Are Taken Up by the Body, and if Either of Them Change How the Body Processes the Other Medicine in Otherwise Healthy Adults With Overweight or Obesity
Lead Sponsor:
Pfizer
Conditions:
Overweight
Obesity
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to see how two study medicines, PF-07976016 and danuglipron, taken together affect the level of each other in the blood of participants who have overweight or obesity. Th...
Eligibility Criteria
Inclusion
- Male and non-pregnant, non-breastfeeding female, 18 to 65 years of age
- BMI 25 to 40 kg/m2 and a total body weight \> 50 kg (110 lb)
- Willing and able to comply with all study procedures including staying a research unit for up to 95 days
Exclusion
- Any medical or psychiatric condition or laboratory abnormality, or recent serious illness or hospitalization, that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study including diagnosis of type 2 diabetes mellitus, type 1 or secondary forms of diabetes
- Use of any prohibited prior or concomitant medication(s)
- Presence of specified abnormalities on diagnostic assessments including clinical laboratory tests
- A positive urine drug test.
- History of alcohol abuse or repeated binge drinking and/or any other illicit drug use or dependence
- Use of tobacco/nicotine containing products in excess of the equivalent of 5 cigarettes/day or 2 chews of tobacco/day
Key Trial Info
Start Date :
March 13 2025
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 20 2025
Estimated Enrollment :
21 Patients enrolled
Trial Details
Trial ID
NCT06910839
Start Date
March 13 2025
End Date
May 20 2025
Last Update
August 7 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Anaheim Clinical Trials, LLC
Anaheim, California, United States, 92801